secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2024-01-23T23:59:59+00:00
Accession:  0001651308-24-000005
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene appoints ex-Sanofi CEO Olivier Brandicourt to board; director Malley resigns
--------------------------------------------------------------------------------

- Thomas Malley resigned from BeiGene board and audit committee on Jan 22, 2024; no disagreement with company operations.
- Olivier Brandicourt, former Sanofi CEO and Blackstone Life Sciences Senior Advisor, appointed to board on Jan 23, 2024.
- Brandicourt will serve on audit committee and receive annual cash comp of $65,000 plus $17,500 for committee service, and pro-rated option valued at $400,000.
- He fills the vacancy created by Malley's resignation and will stand for election at the 2024 annual meeting in June.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000005/0001651308-24-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000005/bgne-20240122.htm
  HTML page:      https://secwatch.observer/filing/0001651308-24-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer